Purpose Of Review: Recent advances in the understanding of the biological basis for thyroid cancer have identified molecular changes in thyroid cancer cells. These changes form the basis for targeted therapies, which have been investigated with some success in patients with advanced, inoperable thyroid cancers and are the subject of this review.
Recent Findings: For patients with advanced differentiated thyroid cancers, sorafenib, selumetinib, pazopanib and sunitinib have been investigated with promising results. In the setting of advanced medullary thyroid cancer, vandetanib now has FDA approval, whereas sorafenib, sunitinib and cabozantinib have shown activity in early studies. For patients with anaplastic thyroid cancer, no targeted therapy has been proven to be effective in vivo, although preclinical work on various kinase inhibitors has shown promise. Despite the potential for disease response, significant cardiac, gastrointestinal and skin-related side effects are reported for all therapies, limiting their application outside the setting of incurable disease.
Summary: Inoperable thyroid cancer still has a poor prognosis, however, the introduction of targeted therapies offers the hope of longer quality of meaningful life for this small group of patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MOO.0b013e32835aa2c2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differentiated thyroid carcinoma (DTC) is the most common endocrine cancer, accounting for 90-95% of thyroid malignancy and predominant in the female population of all age groups. Surgery is the standard primary treatment for patients with DTC, followed by radioactive iodine therapy (RAIT) when indicated. After the main treatment, patients receive thyroid hormone therapy in a variety of regimens, either as a replacement therapy or as a therapy intended to suppress secretion of thyroid-stimulating hormone (TSH).
View Article and Find Full Text PDFIntegration of Circulating Tumor DNA and Metabolic Parameters on F-Fludeoxyglucose Positron Emission Tomography for Outcome Prediction in Unresectable Locally Advanced Non-Small Cell Lung Cancer.
Adv Sci (Weinh)
March 2025
Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
This prospective study explores the prognostic value of circulating tumor DNA (ctDNA) and positron emission tomography/computed tomograpy (PET/CT) in unresectable locally advanced non-small cell lung cancer (LA-NSCLC) treated with definitive chemoradiotherapy (CRT). The discovery set includes 62 patients, with 62 baseline and 53 post-CRT plasma samples. PET/CT is performed at baseline, and 33 patients undergo mid-treatment scans after 40 Gy.
View Article and Find Full Text PDFThyroid cancer.
Semin Perinatol
March 2025
Associate Professor of Clinical Medicine, Division of Endocrinology and Diabetes, Keck School of Medicine of USC, 1333 San Pablo Avenue, BMT-B11, Los Angeles, CA 90033, USA. Electronic address:
Thyroid cancer encountered during pregnancy requires a systematic approach balancing risks and benefits to both maternal and fetal health specific to this unique phase of life. Thyroid nodules are common and are predominantly evaluated to detect thyroid cancer. Clinical examination, serum thyroid stimulating hormone (TSH) measurement, ultrasonographic risk stratification, and fine needle aspiration biopsy when indicated are used to assess for malignancy.
View Article and Find Full Text PDFArtificial base mismatches-mediated PCR (ABM-PCR) for detecting clinically relevant single-base mutations.
Clin Chem Lab Med
March 2025
Department of Biology, College of Science, 12386 Shantou University, Shantou, Guangdong, China.
Objectives: Detecting point mutations with high sensitivity and specificity can be technically very challenging, but it is crucial for early diagnosis and effective drug treatment of cancers. To enable ultrasensitive and ultraspecific detection of single-base mutations in simple and economical ways, we have developed an artificial base mismatches-mediated PCR (ABM-PCR) detection approach.
Methods: ABM-PCR was applied to quantitative PCR (qPCR) and droplet digital PCR (ddPCR) detection platforms.
Papillary thyroid carcinoma and strumal carcinoid transformations of a mature cystic teratoma with NRAS codon 61 mutation: A case report.
Pathol Res Pract
March 2025
Department of Pathology, Shenyang Medical College, No. 146 Road Huanghe North Street, Yuhong District, Shenyang City, Liaoning Province 110034, PR China. Electronic address:
Mature cystic teratoma(MCT) is the most prevalent neoplasm derived from germ cells in females; its progression to malignancy is infrequent. The coexistence of papillary thyroid carcinoma(PTC) and strumal carcinoid derived from MCT is exceptionally rare. To the best of our knowledge, only six cases of this condition have been reported to date, however, the molecular information and immune cell infiltration for the mixture has never been studied.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!